Developmental neurotoxicity of chlorpyrifos: what is the vulnerable period? by Qiao, Dan et al.
Environmental Health Perspectives • VOLUME 110 | NUMBER 11 | November 2002 1097
Developmental Neurotoxicity of Chlorpyrifos: What Is the Vulnerable Period?
Dan Qiao,1 Frederic J. Seidler,1 Stephanie Padilla,2 and Theodore A. Slotkin1
1Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina, USA; 2National Health and
Environmental Effects Research Laboratory, Ofﬁce of Research and Development, U.S. Environmental Protection Agency, Research
Triangle Park, North Carolina, USA
Despite recent restrictions on production for
home use, chlorpyrifos (CPF) remains one of
the most widely used pesticides, and there is
concern over the potential consequences of
fetal and childhood exposure (reviewed in
Landrigan et al. 1999; Pope 1999; Slotkin
1999). The systemic toxicity of CPF primar-
ily reflects cholinergic hyperstimulation as a
result of the inhibition of cholinesterase activ-
ity (Mileson et al. 1998), and immature
organisms are more susceptible to CPF-
induced toxicity than are adults (Moser and
Padilla 1998; Pope and Chakraborti 1992;
Pope et al. 1991; Whitney et al. 1995).
Nevertheless, it is increasingly clear that the
developmental neurotoxicity of CPF involves
mechanisms other than the inhibition of
cholinesterase, with specific targeting of
neural cell replication and differentiation,
axonogenesis, and synaptogenesis (Barone et
al. 2000; Pope 1999; Slotkin 1999). Several
recent studies suggest that CPF affects rela-
tively late events in brain development,
centered around the proliferation, differentia-
tion, and functioning of glial cells (Garcia et
al. 2001, 2002; Qiao et al. 2001), the cells
that provide metabolic support for neurons
and that guide axons to their proper targets
within the developing central nervous system.
In turn, these ﬁndings raise the issue of iden-
tifying the critical window for adverse effects
of CPF on neurodevelopment. If late-occur-
ring processes are involved, then vulnerability
will extend into childhood, a period in which
exposures may be particularly high (Fenske et
al. 1990; Gurunathan et al. 1998; Landrigan
2001; Landrigan et al. 1999).
In our earlier work with postnatal CPF
exposure in rats, we found clear-cut evidence
of cell damage and loss in the immature
brain, as well as interference with the devel-
opment of speciﬁc neural pathways, including
prominent effects on cholinergic innervation
(Dam et al. 1999; Slotkin 1999; Slotkin et al.
2001). Importantly, these effects were all seen
at doses that did not elicit signs of systemic
toxicity (e.g., mortality, body or tissue weight
loss, maternal cannibalism, interference with
suckling). In the present study, we used the
same approach to examine the effects of pre-
natal CPF exposure during two treatment
windows: gestational days (GD) 9–12, corre-
sponding to organogenesis and neural tube
formation, and GD17–20, a peak period of
neurogenesis in the brainstem and forebrain,
the regions exhibiting highest expression of
the cholinergic phenotype. In both cases, we
performed dose–response studies to deter-
mine effects on cell development and cholin-
ergic synaptic markers at doses below the
threshold for maternal or fetal toxicity, and
effects on non-neural tissues such as heart and
liver. Using the established relationship
between DNA levels and cell number
(Winick and Noble 1965), we focused on
indices of cell packing density (DNA per
gram of tissue), cell number (DNA content),
and cell size (protein/DNA ratio), biomarkers
that have been shown to be affected by post-
natal CPF exposure (Campbell et al. 1997;
Dam et al. 1998; Song et al. 1998; Whitney
et al. 1995). For cholinergic synaptic develop-
ment, we assessed choline acetyltransferase
(ChAT), a constitutive marker of cholinergic
nerve terminals (Slotkin et al. 2001); we also
measured radioligand binding to the m2-mus-
carinic acetylcholine receptor (m2AChR), a
mediator of cholinergic signaling that typi-
cally undergoes down-regulation in the pres-
ence of cholinergic hyperstimulation
(Bushnell et al. 1993; Chakraborti et al.
1993; Ward and Mundy 1996) and that may
also be a direct target for CPF actions
(Bomser and Casida 2001; Huff et al. 1994).
Finally, we compared effects on biomarkers
of brain development with the dose–response
curve for inhibition of cholinesterase in the
fetal brain.
Methods
Animal treatments. All experiments were car-
ried out in accordance with the declaration of
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Previously, we found that exposure of neonatal rats to chlorpyrifos (CPF) produced brain cell
damage and loss, with resultant abnormalities of synaptic development. We used the same bio-
markers to examine prenatal CPF treatment so as to define the critical period of vulnerability.
One group of pregnant rats received CPF (subcutaneous injections in dimethyl sulfoxide vehicle)
on gestational days (GD) 17–20, a peak period of neurogenesis; a second group was treated on
GD9–12, the period of neural tube formation. In the GD17–20 group, the threshold for a reduc-
tion in maternal weight gain was 5 mg/kg/day; at or below that dose, there was no evidence
(GD21) of general fetotoxicity as assessed by the number of fetuses or fetal body and tissue
weights. Above the threshold, there was brain sparing (reduced body weight with an increase in
brain/body weight ratio) and a targeting of the liver (reduced liver/body weight). Indices of cell
packing density (DNA per gram of tissue) and cell number (DNA content) similarly showed
effects only on the liver; however, there were significant changes in the protein/DNA ratio, an
index of cell size, in fetal brain regions at doses as low as 1 mg/kg, below the threshold for inhibi-
tion of fetal brain cholinesterase (2 mg/kg). Indices of cholinergic synaptic development showed
significant CPF-induced defects but only at doses above the threshold for cholinesterase inhibi-
tion. With earlier CPF treatment (GD9–12), there was no evidence of general fetotoxicity or alter-
ations of brain cell development at doses up to the threshold for maternal toxicity (5 mg/kg),
assessed on GD17 and GD21; however, augmentation of cholinergic synaptic markers was
detected at doses as low as 1 mg/kg. Compared with previous work on postnatal CPF exposure,
the effects seen here required doses closer to the threshold for fetal weight loss; this implies a
lower vulnerability in the fetal compared with the neonatal brain. Although delayed neurotoxic
effects of prenatal CPF may emerge subsequently in development, our results are consistent with
the preferential targeting of late developmental events such as gliogenesis, axonogenesis, and
synaptogenesis. Key words: brain, chlorpyrifos, choline acetyltransferase, cholinesterase, develop-
ment, heart, liver, muscarinic m2-acetylcholine receptor. Environ Health Perspect 110:1097–1103
(2002). [Online 16 September 2002]
http://ehpnet1.niehs.nih.gov/docs/2002/110p1097-1103qiao/abstract.htmlHelsinki and with the Guide for the Care and
Use of Laboratory Animals as adopted and
promulgated by the National Institutes of
Health. Timed-pregnant Sprague-Dawley rats
were housed in breeding cages with a 12-hr
light–dark cycle and free access to food and
water. CPF was dissolved in dimethyl sulfox-
ide to provide rapid and complete absorption
(Whitney et al. 1995) and was injected sub-
cutaneously in a volume of 1 mL/kg body
weight; control animals received vehicle injec-
tions on the same schedule. One group of
pregnant rats received 0, 1, 2, or 5 mg/kg
daily from GD9 to GD12, and determina-
tions were conducted on GD17 and GD21.
A second group received 0, 1, 2, 5, 10, 20, or
40 mg/kg daily on GD17–20, and determi-
nations were conducted on GD21, 24 hr
after the last dose of CPF. Heart, liver, and
brain were dissected from each fetus, and on
GD21, the brain was separated into forebrain
and brainstem. Tissues were frozen immedi-
ately in liquid nitrogen and stored at –45°C.
Assays. All assay procedures used in this
study have been detailed in previous publica-
tions; accordingly, only brief descriptions are
provided here. For quantitation of macromol-
ecules, DNA was determined using a modi-
fied (Trauth et al. 2000) fluorescent
dye-binding method (Labarca and Piagen
1980) and protein with Folin reagent (Lowry
et al. 1951). Cholinesterase activity was
assayed using an automated spectrophoto-
metric technique, with acetylthiocholine as
the substrate (Padilla et al. 1998). ChAT
activity was measured by the formation of
radiolabeled acetylcholine from [14C]acetyl-
coenzyme A (CoA), as modified (Slotkin et
al. 2001) from earlier procedures (Lau et al.
1988). Radioligand binding to m2AChRs was
determined with [3H]AFDX384, displacing
specific binding with atropine (Song et al.
1997); we used a single, subsaturating ligand
concentration (1 nM) to enable detection of
changes in receptors reflecting either altered
afﬁnity (Kd) or altered capacity (Bmax).
Study design and data analysis. Experi-
ments were conducted on five different
cohorts of animals. In the first group, the
effects of CPF were examined in nonpreg-
nant female rats (average starting weight,
349 ± 3 g) using 11 animals per treatment
group. Two cohorts were used for CPF
exposure on GD9–12, one each for the
experiments carried out on GD17 and
GD21. For this regimen, each treatment
group in each cohort contained 7–10 ani-
mals (average starting weight, 300 ± 3 g).
The final two cohorts were used for CPF
exposure on GD17–20; the first cohort was
used for exposures of 0, 1, 2, and 5 mg/kg
and the second for 0, 10, 20, and 40 mg/kg.
Each treatment group in each cohort con-
tained 7–9 animals (average starting weight,
361 ± 5 g). For presentation purposes, con-
trol values were combined across cohorts,
because they did not differ signiﬁcantly from
each other; however, treatment differences
were established using only the control val-
ues for each matched cohort.
For each determination, the individual
fetus represented a single sample; to avoid bias
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Figure 1. Effects of CPF exposure on maternal body weight gain; presented as the weight change (∆ weight) from the ﬁrst day of injection. (A) CPF effects on non-
pregnant females (ANOVA: treatment, p < 0.0001; treatment × time, p < 0.003). (B) Maternal body weight gain, CPF treatment GD17–20 (ANOVA: treatment, p <
0.0001; treatment × time, p < 0.0001). (C) Maternal body weight gain, CPF treatment GD9–12 (ANOVA: treatment, p < 0.003; treatment × time, p < 0.07). Arrows
denote CPF injections. 
*Individual time points showing signiﬁcant effects, tested only for those dose regimens showing a signiﬁcant overall effect by ANOVA.
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Table 1. CPF treatment on GD17–20: fetal characteristics on GD21.
Treatment Body Forebrain Brainstem Heart Liver Fetuses
(mg/kg/day) weight (g) weight (mg) weight (mg) weight (mg) weight (mg) per dam
0 5.6 ± 0.1 116 ± 2 92 ± 2 25 ± 1 372 ± 9 12.8 ± 0.6
1 5.5 ± 0.1 117 ± 2 94 ± 1 24 ± 1 377 ± 8 13.6 ± 0.8
2 5.4 ± 0.1 115 ± 3 92 ± 1 25 ± 1 376 ± 13 12.3 ± 1.1
5 5.5 ± 0.1 116 ± 2 92 ± 1 24 ± 1 364 ± 13 13.8 ± 0.7
10 4.7 ± 0.4* 114 ± 3 88 ± 3 24 ± 1 284 ± 33* 9.5 ± 0.6*
20 4.0 ± 0.2* 109 ± 2 86 ± 1* 22 ± 1 233 ± 17* 12.4 ± 0.9
40 4.3 ± 0.3* 111 ± 2 88 ± 2 23 ± 1 241 ± 25* 12.8 ± 0.8
ANOVA p < 0.0001 NS p < 0.04 NS p < 0.0001 p < 0.01
NS, not signiﬁcant. ANOVA values across all treatments appear in the bottom row. 
*Individual values that differ signiﬁcantly from the corresponding control, evaluated only where the ANOVA indicated a
signiﬁcant overall treatment effect.
Table 2. CPF treatment on GD9–12: fetal characteristics on GD17.
Treatment Body Brain Heart Liver Fetuses
(mg/kg/day) weight (g) weight (mg) weight (mg) weight (mg) per dam
0 0.84 ± 0.04 78 ± 2 5.3 ± 0.3 70 ± 4 13.6 ± 0.6
1 0.89 ± 0.03 80 ± 3 5.4 ± 0.3 76 ± 3 12.4 ± 0.5
2 0.91 ± 0.02 80 ± 3 5.6 ± 0.2 75 ± 2 11.7 ± 0.9
5 0.92 ± 0.03 81 ± 4 5.8 ± 0.2 77 ± 3 12.9 ± 1.3
ANOVA indicates no significant differences among treatments; there were also no significant differences for ratios of 
tissue/body weights (data not shown).
Table 3. CPF treatment on GD9–12: fetal characteristics on GD21.
Treatment Body Forebrain Brainstem Heart Liver Fetuses
(mg/kg/day) weight (g) weight (mg) weight (mg) weight (mg) weight (mg) per dam
0 5.7 ± 0.2 116 ± 2 90 ± 2 26 ± 1 401 ± 12 11.5 ± 1.0
1 5.8 ± 0.2 117 ± 3 93 ± 2 26 ± 1 411 ± 15 11.4 ± 0.6
2 6.0 ± 0.1 121 ± 4 93 ± 1 28 ± 1 414 ± 6 12.6 ± 0.8
5 5.9 ± 0.1 121 ± 6 94 ± 1 29 ± 1 410 ± 9 11.9 ± 0.7
ANOVA indicates no significant differences among treatments; there were also no significant differences for ratios of 
tissue/body weights (data not shown).from repeated sampling of the same litter,
each dam contributed only one fetus to a
given determination. In general, differences
among treatment groups were established by
multivariate analysis of variance (ANOVA;
treatment, age, tissue), with data log-trans-
formed because of heterogeneous variance.
However, before separate examination of the
measurement variables, we performed a nested
ANOVA across all measurements for the
fetuses from a given dam and found signifi-
cant treatment × measurement interactions (p
< 0.0001), justifying the separation of the
measures. We then subdivided the measures
into three groupings: body and tissue weights,
cell development markers (DNA, protein),
and cholinergic markers (ChAT, m2AChR
binding, cholinesterase) and performed the
nested ANOVA on each grouping. Again,
there were highly signiﬁcant treatment × mea-
surement interactions. Accordingly, data were
separated into the individual measures, which
were then evaluated by ANOVA; where
appropriate, this was followed by post hoc eval-
uations of each treatment group compared
with the controls with Dunnett’s t-test, using
untransformed data. Signiﬁcance was assumed
at the level of p < 0.05 for main effects; how-
ever, for interactions at p < 0.1, we also exam-
ined whether lower-order main effects were
detectable after subdivision of the interactive
variables (Snedecor and Cochran 1967).
Data are presented as means and standard
errors of the mean. To facilitate comparisons
across multiple tissues, ages, and variables,
some results are given as the percentage
change from the corresponding control group,
but statistical comparisons were conducted
only on the original data.
Materials. Animals were purchased from
Zivic Laboratories (Pittsburgh, PA), and CPF
was obtained from Chem Service Inc. (West
Chester, PA). Dimethyl sulfoxide was pur-
chased from Mallinckrodt Baker (Paris, KY).
[14C]Acetyl-CoA (specific activity, 44
mCi/mmol; diluted with unlabeled compound
to 6.7 mCi/mmol) and [3H]AFDX384 (spe-
cific activity, 133 Ci/mmol) were obtained
from PerkinElmer Life Sciences (Boston, MA).
Sigma Chemical Co. (St. Louis, MO) was the
source of all other chemicals.
Results
Repeated administration of CPF, given to
nonpregnant female rats, had no effect on
body weights at 10 mg/kg/day, but animals
lost signiﬁcant amounts of weight at doses of
20 mg/kg/day or higher (Figure 1). In con-
trast, pregnant rats were more sensitive to
CPF, as assessed by this index of systemic tox-
icity. Treatment on GD17–20 showed
impaired weight gain at 5 mg/kg/day and out-
right weight loss at 10, 20, and 40 mg/kg/day.
Similarly, impaired weight gain was seen at 5
mg/kg/day when CPF was given on GD9–12,
but the pregnant rats regained normal weights
by GD14. The differences in maternal weight
gain evoked by CPF treatment did not simply
reﬂect a reduction in the weight of the fetuses
(Tables 1–3). For example, on GD21, dams
in the three highest dose groups for treatment
on GD17–20 showed weight deﬁcits of 80 g,
whereas the reductions in fetal weight totaled
only 15–25 g. This discrepancy indicated that
the dose–response relationship for fetotoxicity
differed from that of maternal toxicity;
accordingly, we examined growth parameters
and neurochemical characteristics of the
fetuses exposed to CPF in the two treatment
windows.
CPF treatment on GD17–20. CPF given
during the later treatment window failed to
cause fetal weight reductions at doses up to
the threshold for maternal weight deﬁcits (5
mg/kg/day) but did evoke fetal weight loss
above that dose (Table 1). The weight deﬁcits
were present regardless of the fact that there
was little or no fetal resorption. The fore-
brain, brainstem, and heart all showed rela-
tive growth sparing, because, with only one
exception, there were no significant differ-
ences at any dose level. In contrast, liver
weights showed robust reductions at doses
above the threshold for maternal toxicity.
The sparing of brain and heart and targeting
of the liver were readily apparent when
weight characteristics were compared as ratios
to fetal body weight (Figure 2): At doses
above 5 mg/kg/day, the brain/body and
heart/body weight ratios were significantly
elevated, whereas the liver/body weight ratio
was reduced. Examination of biomarkers of
cell development gave insight into the under-
lying mechanisms. DNA concentration
showed only small, inconsistent changes,
indicating maintenance of cell packing den-
sity. Accordingly, the hepatic DNA content
was reduced, indicating that the reductions in
weight reﬂected a deﬁcit in the total number
of cells; this was partially offset by an increase
in the relative size of the remaining cells, evi-
denced by augmentation of the protein/DNA
ratio. The cell size marker also indicated that,
despite the sparing of brain weight, cell pack-
ing density, and cell number, CPF evoked
alterations in cell size at doses below the
threshold for general maternal or fetal toxic-
ity. At the two lowest CPF doses, cell size was
enhanced in the brainstem and reduced in the
forebrain, effects that were statistically signiﬁ-
cant overall by ANOVA as well as individu-
ally in post hoc tests. Signs of cell enlargement
were also seen in the heart but only at doses
exceeding the threshold for general growth
impairment.
The heterogeneity of cell and neuron
types in the brain limits the degree of change
for biomarkers of general cell development,
because affected subpopulations are diluted
with unaffected cells or regions. Accordingly,
given the profound effect of CPF on acetyl-
choline systems, we next examined effects on
Articles • Developmental neurotoxicity of chlorpyrifos
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Figure 2. Effects of CPF (GD17–20) on biomarkers of cell development, assessed on GD21, presented as the
percentage change from corresponding control values. (A) Relative tissue weights (ANOVA: treatment, p <
0.0001; treatment × tissue, p < 0.0001); (B) DNA concentration (ANOVA: treatment × tissue, p < 0.009); (C)
DNA content (ANOVA: treatment, p < 0.003; treatment × tissue, p < 0.0001); (D) protein/DNA ratio (ANOVA:
treatment, p < 0.0001; treatment × tissue, p < 0.0001). 
*Individual points showing signiﬁcant effects, tested only for those tissues showing a signiﬁcant overall effect by ANOVA.
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(Figure 3). Administration of 1 mg/kg/day of
CPF on GD17–20 had no significant effect
on cholinesterase activity in fetal brain,
assessed on GD21, 24 hr after the last dose.
However, significant inhibition (15–20%)
was seen at 2 mg/kg/day, rising to 80% inhi-
bition at 40 mg/kg/day. There was a consis-
tent difference in the degree of inhibition
between the two brain regions, with slightly
greater effects on the forebrain compared
with the brainstem. In contrast to the inhibi-
tion of cholinesterase, CPF had a smaller
effect on ChAT activity, a marker for devel-
opment of presynaptic cholinergic nerve ter-
minals. Reductions in ChAT were seen at all
doses but did not achieve statistical signifi-
cance until a threshold of 20 mg/kg/day, and
even then, the maximum deficit was 10%.
Larger deﬁcits were seen for effects of CPF on
developing m2AChRs, with up to a 20%
deﬁcit across both brain regions and a thresh-
old of 5 mg/kg/day. Cardiac m2AChRs
showed similar deﬁcits.
Control values from which the CPF-
induced changes were calculated were, for tissue
weight ratios, 0.0371 ± 0.0006 for brain/body,
0.00439 ± 0.00007 for heart/body, 0.067 ±
0.002 for liver/body; for DNA concentration,
2.84 ± 0.07 mg/g for forebrain, 1.55 ± 0.04
mg/g for brainstem, 2.33 ± 0.06 mg/g for
heart, 1.77 ± 0.07 mg/g for liver; for DNA
content, 0.33 ± 0.01 mg for forebrain, 0.139 ±
0.003 mg for brainstem, 0.055 ± 0.002 mg for
heart, 0.67 ± 0.02 mg for liver; for
protein/DNA ratio, 23.4 ± 0.4 for forebrain,
39.8 ± 0.6 for brainstem, 41.2 ± 0.8 for heart,
56 ± 2 for liver; for cholinesterase, 1,342 ± 64
nmol/min/g tissue for forebrain, 4,827 ± 111
for brainstem; for ChAT, 18.8 ± 0.6
pmol/min/mg protein for forebrain, 52 ± 1 for
brainstem; for m2AChR binding, 88 ± 5
fmol/mg protein in forebrain, 202 ± 9 in brain-
stem, 303 ± 7 in heart.
CPF treatment on GD9–12. In light of
the threshold of 5 mg/kg/day for maternal
toxicity, we limited our examinations of CPF
effects in the earlier treatment window to
doses up to that threshold. With these regi-
mens, CPF had no signiﬁcant effects on fetal
body or tissue weights assessed on GD17 and
GD21, nor were there effects on the number
of fetuses (Tables 2 and 3); ratios of tissue to
body weights were unaltered (data not
shown). As noted for exposure on GD17–20,
treatment on GD9–12 did not affect DNA
concentration at doses up to the threshold for
maternal weight impairment (Figure 4A).
However, total cell number, as indexed by
DNA content (Figure 4B), showed signiﬁcant
changes in multiple tissues. There was an
increase in cardiac DNA content, whereas the
liver showed a biphasic effect, with increases
on GD17 and decreases on GD21. There was
also an increase in hepatic cell size (protein/
DNA ratio; Figure 4C) on GD21, and with
this regimen, the threshold for the effect was
lower than with the later CPF treatment (2
vs. 10 mg/kg/day). For the brain, there was a
consistent overall pattern (p < 0.04) of
reduced cell size at low doses of CPF (Figure
4C), with loss or reversal of the effect at the
highest dose.
As with GD17–20 treatment, these subtle
abnormalities suggested that more robust
changes might be revealed for developmental
markers specific for cholinergic systems
(Figure 5). Low doses of CPF given on
GD9–12 evoked significant elevations of
ChAT in whole brain assessed on GD17, and
again we saw a loss or reversal of the effect at
the higher dose of 5 mg/kg/day. A similar
pattern was seen for m2AChRs on GD17, as
confirmed by comparisons across the two
cholinergic markers: main effect of CPF (p <
0.03) without an interaction of treatment ×
measure; p < 0.04 for control versus CPF 1
mg/kg/day; p < 0.02 for control versus CPF 2
mg/kg/day; no significant difference for 5
mg/kg/day. By GD21, elevations of ChAT
were no longer evident, and suppression was
seen at the highest dose; m2AChR binding no
longer showed any elevations and tended to
be reduced (not significant by itself but also
statistically indistinguishable from the signiﬁ-
cant reductions seen for ChAT).
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Figure 4. Effects of CPF (GD9–12) on biomarkers of cell development, assessed on GD17 and GD21, presented as the percentage change from corresponding con-
trol values. (A) DNA concentration (ANOVA: NS); (B) DNA content (ANOVA: treatment × age × tissue, p < 0.02; heart, p < 0.03; liver, p < 0.05); (C) protein/DNA ratio
(ANOVA: treatment, p < 0.03; treatment × age × tissue, p < 0.007; brain, p < 0.04; liver, p < 0.005). 
*Individual values showing signiﬁcant effects, determined only where the ANOVA indicated a signiﬁcant overall difference for the speciﬁed tissue.
A B C
40
30
20
10
0
–10
–20
0125
CPF (mg/kg/day)
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
c
o
n
t
r
o
l
CPF (mg/kg/day)
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
c
o
n
t
r
o
l
0125
CPF (mg/kg/day)
P
e
r
c
e
n
t
 
c
h
a
n
g
e
 
f
r
o
m
 
c
o
n
t
r
o
l
Whole brain GD17
Heart GD17
Liver GD17
Forebrain GD21
Brainstem GD21
Heart GD21
Liver GD21
40
30
20
10
0
–10
–20
*
*
* * *
40
30
20
10
0
–10
–20
0125
Figure 3. Effects of CPF (GD17–20) on cholinergic markers, assessed on GD21, presented as the percentage change from corresponding control values. (A)
Cholinesterase (ANOVA: treatment, p < 0.0001; treatment × tissue, p < 0.0001); (B) ChAT (ANOVA: treatment × tissue, p < 0.1); (C) m2-AChRs (ANOVA: treatment, p <
0.0001). 
*Individual values showing signiﬁcant effects, tested only where the ANOVA indicated a signiﬁcant interaction of treatment × tissue; in the absence of an interaction, we tested only the
main treatment effect at each dose, shown below each cluster of bars.
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p < 0.0001Control values from which the CPF-
induced changes were calculated were, for
DNA concentration, 2.3 ± 0.1 mg/g tissue for
brain on GD17, 1.28 ± 0.07 for heart on
GD17, 2.73 ± 0.06 for liver on GD17, 3.28 ±
0.02 for forebrain on GD21, 1.68 ± 0.04 for
brainstem on GD21, 2.67 ± 0.07 for heart on
GD21, 1.46 ± 0.11 for liver on GD21; for
DNA content, 0.176 ± 0.008 mg for brain on
GD17, 0.0121 ± 0.0008 for heart on GD17,
0.56 ± 0.03 for liver on GD17, 0.384 ± 0.007
for forebrain on GD21, 0.145 ± 0.004 for
brainstem on GD21, 0.069 ± 0.004 for heart
on GD21, 0.61 ± 0.05 for liver on GD21; for
protein/DNA ratio, 25 ± 1 for brain on
GD17, 28.9 ± 0.5 for heart on GD17, 48.7 ±
0.7 for liver on GD17, 18.8 ± 0.4 for fore-
brain on GD21, 31.6 ± 0.8 for brainstem on
GD21, 40 ± 1 for heart on GD21, 71 ± 4 for
liver on GD21; for ChAT, 13.6 ± 0.3
pmol/min/mg protein for brain on GD17,
25.7 ± 0.7 for forebrain on GD21, 69 ± 6 for
brainstem on GD21; for m2AChR binding,
45 ± 2 fmol/mg protein for brain on GD17,
124 ± 2 for heart on GD17, 80 ± 4 for fore-
brain on GD21, 197 ± 9 for brainstem on
GD21, 276 ± 9 for heart on GD21.
Discussion
Previous work established the selective devel-
opmental neurotoxicity of CPF in the postna-
tal period, characterized by cell damage and
loss, impaired synaptogenesis, and deﬁcits in
synaptic function and related behaviors
(Barone et al. 2000; Pope 1999; Slotkin
1999), all of which occur with threshold
doses below those required for growth
impairment. In contrast, the present results
with fetal CPF exposure indicate relative spar-
ing of major aspects of brain development
beyond the point of outright fetotoxicity.
Accordingly, with late gestational CPF treat-
ment, fetal brain cell number, cell packing
density, and cell size were all maintained even
at 40 mg/kg/day, a dose that caused 80%
inhibition of brain cholinesterase and signiﬁ-
cant fetal growth impairment. In fact, at least
in terms of growth, the fetus was generally
spared compared with the dam: fetal weight
was reduced only at or above 10 mg/kg/day, a
dose that produced > 50% inhibition of fetal
brain cholinesterase, whereas maternal weight
gain was impaired at 5 mg/kg/day. Our
results for biomarkers of general aspects of
brain cell development are compatible with
the sparing of fetal and brain growth noted in
earlier studies with different routes of admin-
istration (Maurissen et al. 2000).
We are thus faced with the likelihood, at
least with these particular biomarkers, that
the neonate is more sensitive to CPF-induced
developmental neurotoxicity than is the fetus.
There are several potential reasons for this
basic difference. First, the fetus recovers far
more readily from cholinesterase inhibition
than do older animals because of the expedi-
tious replacement of cholinesterase molecules
during rapid brain growth (Lassiter et al.
1998; Meneguz et al. 1989); accordingly, sys-
temic toxicity related to cholinergic hyperac-
tivity is likely to be less persistent in the fetus.
Differences in the rate of resynthesis of
cholinesterase may also account for the
smaller effects on enzyme activity in the
brainstem compared with forebrain; certainly,
pharmacokinetic disparities between these
two regions would seem extremely unlikely.
Second, recent data suggest that CPF targets
development of glial cells to a greater extent
than it does neuronal cell development
(Aschner 2000; Garcia et al. 2001, 2002;
Monnet-Tschudi et al. 2000; Qiao et al.
2001); glial development peaks during the
postnatal period (Guerri and Renau-Piqueras
1997; Valles et al. 1997; Zawia and Harry
1996), whereas neurogenesis occurs much
earlier (Rodier 1988), so the neonatal brain
may be inherently more sensitive to CPF than
is the fetal brain. Third, in light of the recent
recognition that CPF itself is a developmental
neurotoxicant (Barone et al. 2000; Pope
1999; Rice and Barone 2000; Slotkin 1999),
over and above inhibition of cholinesterase by
its metabolite, chlorpyrifos oxon, there are
likely to be substantial differences of effects
reflecting the dissimilarities in fetal versus
neonatal pharmacokinetics (Hunter et al.
1998, 1999; Moser et al. 1998; Padilla et al.
2000); it is highly likely that more unchanged
CPF reaches the neonatal brain after direct
administration to pups than is achieved with
fetal exposure paradigms that involve mater-
nal administration (Hunter et al. 1998).
Notwithstanding these factors, it is also
likely that the basic markers of cell develop-
ment used here provide an inadequate basis for
concluding that there are no adverse effects of
prenatal CPF exposure. DNA and protein-
based biomarkers require the use of fairly large
brain regions, so effects on a targeted subre-
gion or population of cells can be masked by a
relatively larger, unaffected population. In that
case, effects would only emerge at high doses
that elicit general fetotoxicity. Indeed, when
we examined markers specific to cholinergic
synaptic development, we saw more robust
changes at lower doses of CPF, effects similar
in magnitude to those elicited by postnatal
CPF exposure (Chakraborti et al. 1993; Dam
et al. 1999; Slotkin et al. 2001). With these
markers, we found significant deficits with
treatment on GD17–20, even at 5 mg/kg/day,
a dose that did not evoke fetal growth impair-
ment. It is therefore likely that examination of
smaller subregions, combined with the use of
dynamic markers that provide sensitive indices
of cholinergic synaptic function (Dam et al.
1999; Slotkin et al. 2001), will reveal fetal
anomalies. Indeed, two preliminary reports
suggest that prenatal CPF exposure can disrupt
architectural organization of specific subre-
gions, including apoptosis and changes in cell
migration (Lassiter et al. 2002; White et al.
2002). It also must be noted that, even with
postnatal CPF exposure, many of the neuro-
toxic effects appear only after a delay (Barone
et al. 2000; Landrigan et al. 1999; Pope 1999;
Ray and Richards 2001; Rice and Barone
2000; Slotkin 1999), whereas in the present
study we have assessed only the immediate
fetal effects. Accordingly, a deﬁnitive evalua-
tion of the consequences of fetal exposure will
require a longitudinal study from early devel-
opment through adulthood, using doses span-
ning the threshold for fetotoxicity; a few
reports that have appeared on this issue suggest
that neurobehavioral deﬁcits emerge after fetal
CPF exposure (Chanda and Pope 1996; Muto
et al. 1992), but no underlying synaptic mech-
anisms have as yet been identiﬁed.
Our findings suggest that the effects of
CPF on fetal brain development are funda-
mentally different for exposure in early
(GD9–12) compared with late (GD17–20)
gestation. Exposure during the earlier period
evoked an augmentation in cholinergic
synaptic markers instead of the deficits seen
with later treatment. The biphasic nature of
the dose–response curve for effects of treat-
ment on GD9–12 gives some clue as to the
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Figure 5. Effects of CPF (GD9–12) on cholinergic markers, assessed on GD17 and GD21, presented as the
percentage change from corresponding control values. (A) ChAT (ANOVA: treatment, p < 0.05); (B) m2-
AChRs (ANOVA: heart, p < 0.005).
*Individual values showing signiﬁcant effects and main treatment effects across multiple tissues are shown the bar clusters.
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p < 0.03underlying events: Promotional effects were
seen only at low doses (1 or 2 mg/kg/day) but
were offset by a higher dose (5 mg/kg/day)
that impaired maternal weight gain. During
brain development, acetylcholine serves as a
trophic factor, regulating the differentiation of
target cells containing cholinergic receptors
(Hohmann and Berger-Sweeney 1998;
Morley and Happe 2000; Navarro et al. 1989;
Slotkin 1999), and its precursor and break-
down product, choline, also augments neural
plasticity (Cermak et al. 1999; Montoya et al.
2000). It is thus possible that during early ges-
tation, low CPF exposures elicit promotional
effects on neural cell differentiation that are
offset when doses are raised to the point of
cellular or general fetotoxicity; indeed, we
found previously that high CPF exposures
elicit apoptosis in fetal brain during this stage
of development (Roy et al. 1998). Generation
of reactive oxygen species provides an addi-
tional potential mechanism for dual effects of
CPF: Mild oxidative stress can induce cell dif-
ferentiation (Katoh et al. 1997), whereas
excessive formation of reactive oxygen species
results in cell damage. Careful examination of
the biomarkers for the later exposure para-
digm (GD17–20) also provides some indica-
tion for a dual spectrum of CPF actions. Low
doses of CPF evoked a slight but significant
enhancement of cell growth in the brainstem
(increased protein/DNA ratio), an effect that
was lost when the dose was raised above the
threshold for fetotoxicity. Our results thus
point to a shifting spectrum of CPF effects on
neurodevelopment, dependent both on the
exposure window and on the dose.
In addition to the impact on neurodevel-
opment, CPF had robust effects on the fetal
liver. Indeed, the deﬁcits in liver weight were
larger than those for body weight, so this tis-
sue was selectively targeted. The underlying
mechanism involved a decline in the number
of liver cells (reduced DNA), with some com-
pensatory cell enlargement (protein/DNA), so
the degree of tissue weight loss was less than
would have been expected from the deﬁcit in
cell number. Although we do not yet have
information about the reason for hepatic cell
loss, there are a number of likely possibilities.
The antimitotic effects of CPF (Barone et al.
2000; Campbell et al. 1997; Dam et al. 1998;
Garcia et al. 2001; Qiao et al. 2001; Song et
al. 1998; Whitney et al. 1995) could target
the fetal liver because of its extremely rapid
rate of cell acquisition and because this tissue
achieves high levels of CPF and its metabolites
(Hunter et al. 1999). Additionally, the oxida-
tive stress caused by CPF is likely to evoke
hepatic cell damage and loss (Crumpton et al.
2000; Garcia et al. 2001; Jett and Navoa
2000), so sensitivity could depend on the rela-
tive state of development of enzymes generat-
ing reactive oxygen species, compared with
those required for the deactivation of free rad-
icals and/or catabolism of CPF (Padilla et al.
2000). In any case, the effects on the fetal liver
stand in direct contrast to the pattern seen for
exposure in the neonatal period: postnatal
CPF, which has a profound effect on brain
cell development (Barone et al. 2000; Pope
1999; Rice and Barone 2000; Slotkin 1999),
does not evoke substantial deficits in liver
weight (Auman et al. 2000); however, it does
alter cell signaling cascades linked to neuro-
transmitter receptors (Auman et al. 2000),
reinforcing the concept that, as in the devel-
oping brain, disruption of CPF-induced cell-
to-cell communication is separable from
generalized toxicity or growth impairment.
Obviously, future work should address the
potential impact of fetal or neonatal CPF
exposure on liver function and, in particular,
hepatic responses to neuronal/hormonal
inputs using the affected signaling cascades.
In conclusion, our results indicate that
fetal CPF exposure elicits far less widespread
cell damage and loss in the fetal nervous sys-
tem compared with postnatal CPF exposure.
Nevertheless, we found indications of more
subtle alterations in specific regions and cell
or synaptic populations that suggest the need
for further identification of the neurotrans-
mitter systems affected by CPF exposure.
Longitudinal studies of later-emerging synap-
tic and behavioral alterations will be required
to characterize the functional consequences of
these effects.
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